Allergan obtained its first FDA approval for Botox in 1989, and has systemically been able to get new uses approved that will keep it the frontrunner forever.
This is an entirely separate issue from AGN’s Restasis ploy. I see nothing improper about AGN’s testing Botox in new indications; to the contrary, as a RVNC long I’m happy to piggyback off of AGN’s new clinical investigations.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”